[PDF][PDF] Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941
TT Junttila, RW Akita, K Parsons, C Fields, GDL Phillips… - Cancer cell, 2009 - cell.com
TT Junttila, RW Akita, K Parsons, C Fields, GDL Phillips, LS Friedman, D Sampath…
Cancer cell, 2009•cell.comHerceptin (trastuzumab) is the backbone of HER2-directed breast cancer therapy and
benefits patients in both the adjuvant and metastatic settings. Here, we describe a
mechanism of action for trastuzumab whereby antibody treatment disrupts ligand-
independent HER2/HER3 interactions in HER2-amplified cells. The kinetics of dissociation
parallels HER3 dephosphorylation and uncoupling from PI3K activity, leading to
downregulation of proximal and distal AKT signaling, and correlates with the antiproliferative …
benefits patients in both the adjuvant and metastatic settings. Here, we describe a
mechanism of action for trastuzumab whereby antibody treatment disrupts ligand-
independent HER2/HER3 interactions in HER2-amplified cells. The kinetics of dissociation
parallels HER3 dephosphorylation and uncoupling from PI3K activity, leading to
downregulation of proximal and distal AKT signaling, and correlates with the antiproliferative …
Summary
Herceptin (trastuzumab) is the backbone of HER2-directed breast cancer therapy and benefits patients in both the adjuvant and metastatic settings. Here, we describe a mechanism of action for trastuzumab whereby antibody treatment disrupts ligand-independent HER2/HER3 interactions in HER2-amplified cells. The kinetics of dissociation parallels HER3 dephosphorylation and uncoupling from PI3K activity, leading to downregulation of proximal and distal AKT signaling, and correlates with the antiproliferative effects of trastuzumab. A selective and potent PI3K inhibitor, GDC-0941, is highly efficacious both in combination with trastuzumab and in the treatment of trastuzumab-resistant cells and tumors.
cell.com